<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39404351</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>Cyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>e0127624</StartPage><MedlinePgn>e0127624</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/spectrum.01276-24</ELocationID><Abstract><AbstractText Label="UNLABELLED">This study aimed to explore the effect of cyclosporine (CsA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in systemic lupus erythematosus (SLE) patients to provide a valuable reference for clinical treatment strategies in the context of the long-term risk of SARS-CoV-2 infection. SLE patients who visited the Rheumatology Outpatient Department of Fujian Medical University Union Hospital between 1 May and 31 October 2022 were included. Data on SARS-CoV-2 infection in patients between 1 November 2022 and 31 July 2023 were obtained by telephone follow-up. Patients were divided into two groups according to whether CsA was used during the observation period: the glucocorticoid or hydroxychloroquine group and the CsA group. To assess the robustness of the results, Data sets 1 and 2 were established to be analyzed independently. Multivariate logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for symptomatic coronavirus disease (COVID-19). A total of 184 patients were included, among whom 129 were definite symptomatic COVID-19 patients; 29 were presumptive symptomatic COVID-19 patients; and 4 had signs and symptoms of COVID-19, but tested negative for SARS-CoV-2 in a virological test. According to the multivariable-adjusted models, CsA was associated with lower odds of symptomatic COVID-19 (<i>P</i> = 0.042, OR = 0.316, 95% CI: 0.104-0.959 in Data set 1 and <i>P</i> = 0.021, OR = 0.257, 95% CI: 0.081-0.812 in Data set 2). CsA is associated with lower odds of contracting symptomatic COVID-19. The use of CsA may be considered an appropriate therapeutic option for disease management in patients with rheumatic diseases who have severe disease activity and persistent SARS-CoV-2 infection.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Our study indicated that cyclosporine may reduce the risk of symptomatic COVID-19 in systemic lupus erythematosus patients in spite of its immunosuppressive effects. This study provides a reference for clinical treatment strategies for AIIRD patients in the context of the long-term risk of SARS-CoV-2 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>He-Jun</ForeName><Initials>H-J</Initials><Identifier Source="ORCID">0000-0001-9179-8887</Identifier><AffiliationInfo><Affiliation>Fujian Institute of Clinical Immunology, Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lin</LastName><ForeName>Shu-Huan</ForeName><Initials>S-H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yan-Qing</ForeName><Initials>Y-Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xiang-Xiong</ForeName><Initials>X-X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Li-Xin</ForeName><Initials>L-X</Initials><Identifier Source="ORCID">0000-0003-1078-9087</Identifier><AffiliationInfo><Affiliation>Fujian Institute of Clinical Immunology, Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology, Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cyclosporine</Keyword><Keyword MajorTopicYN="N">immunosuppressive therapy</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>9</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39404351</ArticleId><ArticleId IdType="doi">10.1128/spectrum.01276-24</ArticleId></ArticleIdList></PubmedData></PubmedArticle>